Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
761-780 of 1,738 trials

Head and Neck Cancer: New Treatment Combinations

We are comparing a new drug combination with a single drug for patients with locally advanced head and neck cancer. The aim is to see which treatment works better before starting chemoradiotherapy.

Locally Advanced Head and Neck Squamous Cell Carcinoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Vitamin C Treatment for Cardiac Surgery Patients

We are studying whether vitamin C can reduce inflammation and improve recovery in patients undergoing cardiac surgery. This trial compares vitamin C treatment to standard care to see which is more effective.

Cardiovascular Illness>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Advanced Solid Tumors: MOST Plus Treatment Study

We are studying a new maintenance treatment for patients with advanced solid tumors to see if it helps keep the disease stable after initial therapy. This trial compares ongoing treatment with stopping the therapy to understand the best approach.

Advanced or Metastatic Cancers>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Advanced Cancer: Targeted Therapy Study

We are evaluating new treatments that specifically target the molecular changes in tumors of patients with advanced or metastatic cancer. The goal is to see how well these therapies work and their safety profile.

Advanced / Metastatic Cancers>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Pancreatic Cancer: Personalized FOLFIRINOX Dosing Study

We are exploring how personalized dosing of the chemotherapy drug 5-FU affects safety and treatment outcomes in pancreatic cancer patients. This study aims to find the best dosing strategy to improve effectiveness and minimize side effects.

Pancreatic Cancer3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyOncology

Rhabdomyosarcoma: New Treatment Combinations

We are studying new chemotherapy and radiotherapy options for children and adults with Rhabdomyosarcoma. The goal is to see if these new treatments improve outcomes compared to standard therapies.

RhabdomyosarcomaSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncologyPediatrics

Systemic Lupus Erythematosus: Obexelimab Study

We are studying a new medication, Obexelimab, for patients with systemic lupus erythematosus to see if it can lower disease activity and reduce fatigue. This trial compares its effects to a placebo treatment.

Systemic Lupus Erythematosus6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInternal MedicineRheumatology

Intranasal COVID-19 Vaccine: LVT-001

We are studying a new intranasal booster vaccine for COVID-19 to see if it is safe and more effective than the standard mRNA vaccine. This trial is for healthy adults who want to help improve COVID-19 vaccination strategies.

COVID-191-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementInfectious Diseases

Ovarian Cancer: 5-ALA Imaging Study

We are testing a dye called 5-ALA to see if it helps surgeons find ovarian cancer tumors that regular methods might miss. This study aims to improve tumor detection during surgery.

Ovarian Cancer≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGynecology and ObstetricsOncologyOtolaryngology

Parkinson's Disease: New Approaches to Levodopa Resistance

We are studying whether the medication apomorphine or the antibiotic rifaximin can help people with Parkinson's disease who struggle with levodopa treatment. This trial aims to improve their symptoms and overall treatment response.

Parkinson's Disease6-12 monthsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementInternal MedicineNeurology

Acute Myeloid Leukemia: Venetoclax and Azacitidine Treatment

We are studying whether a combination of venetoclax and azacitidine can help clear residual disease in AML patients before a stem cell transplant. This trial also looks at the safety and effectiveness of this treatment approach.

Acute Myeloid Leukemia>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsNo PlaceboStandard MedicinesHematologyOncology

Advanced Solid Tumors: BT5528 Treatment Study

We are testing a new drug, BT5528, for patients with advanced solid tumors that express EphA2. The study aims to evaluate its safety and effectiveness, both alone and with another medication.

Malignant Solid Tumor1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Zanamivir for Infants with Complicated Influenza

We are studying how safe and effective intravenous zanamivir is for hospitalized infants under 6 months with complicated influenza. This research aims to understand how the drug works in young children.

Human Influenza>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious DiseasesPediatrics

DAY101 for Pediatric Brain Cancer and Solid Tumors

We are studying the effects of DAY101 in children aged 6 months to 25 years with low-grade glioma or advanced solid tumors. The goal is to see if it helps shrink tumors and to assess its safety.

Malignant Glioma>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyPediatrics

Mpox Booster Vaccine: Fractional vs. Full Dose

We are studying whether a smaller booster dose of the MVA-BN vaccine is as effective as the standard dose in adults. This trial will also look at the safety and immune response of both doses.

Mpox (Monkeypox)3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious Diseases

Soft Tissue Sarcomas: HDM201 and Pazopanib Study

We are evaluating a new treatment combining HDM201 and Pazopanib for patients with advanced soft tissue sarcomas. The goal is to understand its clinical impact on those with P53 wild-type tumors.

Soft Tissue Sarcoma>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Prostate Cancer: Personalized Radiotherapy and Hormone Therapy

We are studying whether using AI to customize radiotherapy and hormone treatment can help prostate cancer patients while reducing the overall treatment time. This trial is for those with high-risk localized prostate cancer.

Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Soft Tissue Sarcoma: MEK and PDL1 Inhibitor Combination

We are studying a new treatment combining two medications for patients with advanced soft tissue sarcoma. This trial aims to confirm safety and evaluate how well the treatment works in both children and adults.

Advanced or Metastatic CancerSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Soft Tissue Sarcomas: Atezolizumab with Radiotherapy

We are studying whether adding an immunotherapy drug to radiotherapy helps patients with localized soft tissue sarcomas achieve better treatment outcomes. The trial will also look at the safety and immune response to this combination.

Localized Soft Tissue Sarcoma3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncology

VEXAS Syndrome: Azacitidine Treatment Study

We are studying whether Azacitidine can help reduce symptoms and improve health in patients with VEXAS Syndrome. The trial will also assess the safety of this treatment and its impact on patients' quality of life.

VEXAS Syndrome>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteHematologyRheumatology